Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00172-8/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz-_AkXTVIEPipL-JrauLUxSwHsSdEmKfsXguA8TVv2Cg6BTp1nAeUxz4SsZrqkuQHhwJ4EsLGlzsszMLRNd3dJu5ZBdwOA&_hsmi=322652483&utm_content=322446729&utm_source=hs_email